Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaxigrip Tetra
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Vaxigrip Tetra is a quadrivalent, split-virion, inactivated influenza vaccine developed and manufactured by Sanofi Pasteur. It contains purified hemagglutinin (HA) and neuraminidase (NA) antigens from four influenza virus strains—two influenza A strains (H1N1 and H3N2) and two influenza B strains (Victoria and Yamagata lineages)—as recommended by the World Health Organization (WHO). The vaccine is produced using embryonated chicken eggs and is indicated for active immunization against influenza in individuals aged 6 months and older. In the context of research conducted by the Johns Hopkins Bloomberg School of Public Health (the PAIR study), it is being used to investigate the impact of maternal arsenic exposure and micronutrient deficiencies on immune responses to vaccination in pregnant women and their newborns in Bangladesh.
- Brand names
- Vaxigrip Tetra
- Other names
- VaxigripTetraVaxigrip Tetra-Johns Hopkins Bloomberg School of Public Health-influenzaquadrivalent split-virion inactivated influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on Vaxigrip Tetra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxigrip Tetra.